| NCT00196599 | French National Agency for Research on AIDS and Viral Hepatitis|Triangle Pharmaceuticals|Gilead Sciences|Bristol-Myers Squibb|Dupont Applied Biosciences | HIV Infections|Antiretroviral Naive | 1999-02 | PHASE2 |
| NCT00192634 | Kirby Institute | HIV Infections | 2005-12 | PHASE4 |
| NCT00002362 | Triangle Pharmaceuticals | HIV Infections | 1999-08 | PHASE3 |
| NCT00524173 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Hepatitis B | 2007-08-29 | PHASE2 |
| NCT01285050 | Johns Hopkins University|National Institute on Drug Abuse (NIDA) | HIV Infection|Hepatitis C | 2011-01 | PHASE4 |
| NCT04318210 | Centers for Disease Control and Prevention|Botswana Ministry of Health | HIV Infections | 2012-10 | NA |
| NCT03163277 | Giovanni Di Perri | Hiv|Neurocognitive Dysfunction | 2017-05-15 | PHASE4 |
| NCT00705419 | Merck Sharp & Dohme LLC | HIV Infections | 2007-07 | |
| NCT04519125 | Hospital Universitario San Ignacio|Pontificia Universidad Javeriana|Hospital Universitario Nacional de Colombia|Hospital de la Samaritana, Sede Bogotá y Sede Zipaquirá|Hospital Universitario San Jorge, Pereira.|Fundación Universitaria Autónoma de Las Américas|Universidad Tecnológica de Pereira|Colsanitas | Severe Acute Respiratory Syndrome Coronavirus 2|COVID-19 | 2020-08-30 | PHASE2|PHASE3 |
| NCT00042289 | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections | 2003-06-09 | |
| NCT01154673 | University of Toronto|Unity Health Toronto|Maple Leaf Research | Acute HIV Infection | 2011-11 | PHASE2|PHASE3 |
| NCT00724711 | Gilead Sciences | HIV Infection | 2008-07 | PHASE4 |
| NCT00112047 | Gilead Sciences | HIV Infections | 2003-07 | PHASE3 |
| NCT00346567 | Rigshospitalet, Denmark|University of Copenhagen | HIV Infections | 2006-06 | NA |
| NCT00924898 | University of North Carolina, Chapel Hill|Bristol-Myers Squibb|Gilead Sciences | Acute HIV Infection|HIV Infections | 2005-01 | PHASE4 |
| NCT00448669 | Centers for Disease Control and Prevention|Botswana Ministry of Health|Gilead Sciences | HIV Infections | 2007-03 | PHASE2|PHASE3 |
| NCT04477096 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Healthy Subjects | 2020-08-03 | PHASE1 |
| NCT02327715 | Asian-Pacific Alliance of Liver Disease, Beijing|Beijing Ditan Hospital|Hebei Medical University Pharmaceutical Factory|National Health and Family Planning Commission, P.R.China | Hepatitis B, Chronic|Pregnancy | 2015-01 | PHASE4 |
| NCT04329442 | University of Chicago|Planned Parenthood Great Plains | HIV+AIDS | 2020-04-01 | NA |
| NCT00335322 | Kirby Institute|The University of New South Wales | Human Immunodeficiency Virus (HIV) | 2007-02 | PHASE4 |
| NCT03394196 | University of Washington|Clinique des Maladies Infectieuses, CHNU de Fann, Dakar, Senegal|Centre de Sante de Ziguinchor, Casamance, Senegal|Janssen Pharmaceutica|Merck Sharp & Dohme LLC|National Institute of Allergy and Infectious Diseases (NIAID) | HIV-2 Infection | 2018-07-04 | NA |
| NCT00043966 | Abbott | HIV Infections | 2002-07 | PHASE3 |
| NCT00799864 | Janssen Sciences Ireland UC | HIV-1 | 2011-01 | PHASE2 |
| NCT04240509 | The Miriam Hospital | HIV Infections|Sexually Transmitted Diseases | 2019-11-01 | PHASE4 |
| NCT00002335 | Glaxo Wellcome | HIV Infections | | PHASE1 |
| NCT04616963 | University of California, San Diego | Hiv|Hormone Therapy | 2019-10-24 | PHASE4 |
| NCT00662545 | University of California, San Francisco|Bristol-Myers Squibb | HIV Infections|Hepatitis B | 2008-04 | PHASE4 |
| NCT06203132 | ANRS, Emerging Infectious Diseases|MSD France|European and Developing Countries Clinical Trials Partnership (EDCTP) | HIV-1-infection | 2025-01-27 | PHASE3 |
| NCT03309566 | Laboratorio Elea Phoenix S.A. | Healthy | 2016-09-04 | PHASE4 |
| NCT01694407 | CONRAD | HIV | 2013-02 | PHASE1 |
| NCT00017992 | Triangle Pharmaceuticals | HIV Infections | | PHASE2 |
| NCT04367688 | Chinese University of Hong Kong | HIV Infections | 2020-03-01 | |
| NCT03120494 | Puerto Rico Community Network for Clinical Research on AIDS|Gilead Sciences | HIV+AIDS | 2016-11 | PHASE4 |
| NCT00757783 | Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA | HIV | 2008-10 | PHASE4 |
| NCT04585737 | Charlotte-Paige Rolle, MD|ViiV Healthcare | HIV I Infection | 2020-10-05 | PHASE4 |
| NCT05458765 | Eastern Virginia Medical School|CONRAD|FHI 360|United States Agency for International Development (USAID)|Gilead Sciences | Acceptability of Health Care|Adherence, Medication | 2022-06-21 | PHASE2 |
| NCT01326221 | University of North Carolina, Chapel Hill|Gilead Sciences | Pharmacokinetic Study in Healthy Volunteers | 2008-10 | |
| NCT00862823 | University of Alabama at Birmingham|Bristol-Myers Squibb | Healthy | 2009-02 | PHASE4 |
| NCT00016718 | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections | 2001-08 | PHASE1|PHASE2 |
| NCT00006208 | Triangle Pharmaceuticals | HIV Infections | 2000-08 | PHASE3 |
| NCT01505114 | National Institute of Allergy and Infectious Diseases (NIAID)|HIV Prevention Trials Network|Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections | HIV Infection | 2012-06 | PHASE2 |
| NCT01576731 | Hospital Clinic of Barcelona | HIV Infection | 2012-07 | PHASE4 |
| NCT02475915 | SEARCH Research Foundation|Thai Red Cross AIDS Research Centre|Cooper Human Systems | Acute HIV Infection | 2015-01 | PHASE1|PHASE2 |
| NCT02150993 | ANRS, Emerging Infectious Diseases | HIV-2 Infection | 2016-01-26 | PHASE2|PHASE3 |
| NCT00949234 | University of California, Los Angeles|Los Angeles County Department of Public Health|AIDS Project Los Angeles|Los Angeles LGBT Center|The OASIS Clinic | HIV Prevention|HIV Infections | 2010-03 | PHASE2 |
| NCT02968576 | University of Colorado, Denver | Healthy Volunteers|Pharmacokinetics | 2016-12 | NA |
| NCT06807736 | Desmond Tutu HIV Foundation|Bill and Melinda Gates Foundation|ViiV Healthcare | HIV Infection|Sexual and Reproductive Health | 2024-02-13 | |
| NCT01400412 | Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID) | HIV-1 Infection | 2012-01-17 | PHASE2 |
| NCT00552240 | Boehringer Ingelheim | HIV Infections | 2007-09 | PHASE4 |
| NCT00532168 | Juan A. Arnaiz | HIV Infections | 2007-09 | PHASE4 |
| NCT00051831 | National Institute of Allergy and Infectious Diseases (NIAID)|Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections | HIV Infections | 2003-10 | NA |
| NCT00608569 | Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2009-03 | NA |
| NCT07202546 | ViiV Healthcare | HIV Infections | 2026-02-11 | PHASE2 |
| NCT01335620 | Imperial College London | HIV | 2011-04 | PHASE4 |
| NCT01394133 | University of Alabama at Birmingham|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infected | 2011-07 | |
| NCT02327663 | Asian-Pacific Alliance of Liver Disease, Beijing|Beijing Ditan Hospital|Hebei Medical University Pharmaceutical Factory|National Health and Family Planning Commission, P.R.China | Hepatitis B, Chronic | 2014-12 | PHASE4 |
| NCT01781806 | University of California, Los Angeles|Los Angeles County Department of Public Health|Los Angeles LGBT Center|The OASIS Clinic|AIDS Project Los Angeles | HIV Prevention | 2013-05 | PHASE4 |
| NCT04054089 | Cristina Mussini | HIV Infections | 2020-01-23 | PHASE4 |
| NCT00089505 | Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2006-11 | PHASE3 |
| NCT02327689 | Asian-Pacific Alliance of Liver Disease, Beijing|Beijing Ditan Hospital|Hebei Medical University Pharmaceutical Factory|National Health and Family Planning Commission, P.R.China | Hepatitis B, Chronic|Fibrosis | 2015-01 | PHASE4 |
| NCT02065986 | MRC [ycm] | HIV | 2012-10 | PHASE4 |
| NCT05898841 | Fundacion SEIMC-GESIDA | HIV Infections|Fatty Liver Disease | 2023-05-26 | PHASE4 |
| NCT01040091 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2009-12 | PHASE1 |
| NCT00364793 | Bristol-Myers Squibb | HIV Infections | 2007-02 | PHASE1|PHASE2 |
| NCT02116660 | Merck Sharp & Dohme LLC | HIV Infections | 2014-09-03 | PHASE2 |
| NCT03058835 | Rutgers, The State University of New Jersey | PrEP Adherence Monitoring | 2016-09 | PHASE4 |
| NCT00759070 | Juan A. Arnaiz|Fundació Institut de Recerca de l´Hospital de la Santa Creu i Sant Pau|Germans Trias i Pujol Hospital|Hospital Universitari Joan XXIII de Tarragona.|Hospitales Universitarios Virgen del Rocío | HIV Infections | 2008-09 | PHASE4 |
| NCT00869960 | University of Alabama at Birmingham|National Institute of Allergy and Infectious Diseases (NIAID) | Healthy | 2009-03 | PHASE4 |
| NCT00544128 | International Medical Center of Japan|Ministry of Health, Labour and Welfare, Japan | HIV Infections | 2007-10 | PHASE4 |
| NCT01855867 | Kenneth H. Mayer, MD|Gilead Sciences | Human Immunodeficiency Virus | 2013-05 | PHASE4 |
| NCT04583267 | Yonsei University | HIV Infections | 2018-08-28 | NA |
| NCT01033942 | University of North Carolina, Chapel Hill|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH) | HIV | 2009-08 | PHASE2 |
| NCT07476339 | CAN Community Health|Gilead Sciences|Midway Specialty Care Center|Costello Medical Inc. | HIV -1 Infection|HIV (Human Immunodeficiency Virus)|HIV|HIV 1 Infection | 2026-03-23 | PHASE4 |
| NCT01533272 | Hospital Clinic of Barcelona | HIV Infection | 2012-02 | PHASE4 |
| NCT03360682 | Fundacion Clinic per a la Recerca Biomédica | HIV-1-infection|Solid Organ Transplant | 2018-04-13 | PHASE4 |
| NCT01929759 | Massachusetts General Hospital|Brigham and Women´s Hospital|Gilead Sciences | HIV Disease | 2014-01 | NA |
| NCT00158457 | French National Agency for Research on AIDS and Viral Hepatitis|Gilead Sciences|Institut de Médecine et d´Epidémiologie Appliquée - Fondation Internationale Léon M´Ba | HIV Infection | 2004-06 | PHASE3 |
| NCT05979311 | ViiV Healthcare | HIV|HIV Infections | 2024-02-09 | PHASE3 |
| NCT01989611 | Oswaldo Cruz Foundation|University of Sao Paulo|Centro de Referência e Treinamento DST+Aids | HIV | 2014-06 | NA |
| NCT03954327 | University of Alberta|Merck Sharp & Dohme LLC | Primary Biliary Cholangitis | 2021-03-01 | PHASE2 |
| NCT00743340 | Gilead Sciences | HIV-1 Infection | 2005-11-22 | PHASE2 |
| NCT02327676 | Asian-Pacific Alliance of Liver Disease, Beijing|Beijing Ditan Hospital|Hebei Medical University Pharmaceutical Factory|National Health and Family Planning Commission, P.R.China | Hepatitis B, Chronic | 2015-01 | PHASE4 |
| NCT04712357 | Universidade Federal do Ceara|Conselho Nacional de Desenvolvimento Científico e Tecnológico|S?o José Hospital for Infectious Diseases - HSJ|Central Laboratory of Public Health of Ceará - Lacen-CE | Covid19 | 2020-11-09 | NA |
| NCT02198443 | Fundacion Clinic per a la Recerca Biomédica | HIV | 2015-06-06 | PHASE4 |
| NCT02327702 | Asian-Pacific Alliance of Liver Disease, Beijing|Beijing Ditan Hospital|Hebei Medical University Pharmaceutical Factory|National Health and Family Planning Commission, P.R.China | Hepatitis B, Chronic|Pregnancy | 2015-01 | PHASE4 |
| NCT00476463 | The HIV Netherlands Australia Thailand Research Collaboration|Gilead Sciences|Ministry of Health, Thailand | Hepatitis B Virus|HIV Infections | 2005-04 | PHASE2 |
| NCT00036452 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | PHASE2 |
| NCT03220152 | Oswaldo Cruz Foundation | HIV, Prevention | 2017-07-10 | PHASE4 |
| NCT03120936 | Public Health Foundation Enterprises, Inc.|San Francisco Department of Public Health|University of California, San Francisco|San Francisco Community Health Center|Tri-City Health Center|California HIV+AIDS Research Program | Transgender Persons|Pre-Exposure Prophylaxis | 2017-08-08 | PHASE4 |
| NCT07210528 | National University Hospital, Singapore | Mild Cognitive Impairment (MCI)|Alzheimer Dementia (AD) | 2025-06-30 | PHASE1 |
| NCT06250504 | Africa Health Research Institute | HIV Infections | 2024-02-27 | PHASE3 |
| NCT03304717 | Children´s Hospital of Philadelphia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Human Genome Research Institute (NHGRI)|Gilead Sciences|Emerson Resources|National Institutes of Health (NIH) | Aicardi Goutières Syndrome | 2025-12 | PHASE1|PHASE2 |
| NCT00106379 | Gilead Sciences | HIV Infections | 2004-10 | PHASE4 |
| NCT02962739 | University of Colorado, Denver | Healthy Volunteers | 2016-03 | PHASE1 |
| NCT01803074 | ViiV Healthcare|GlaxoSmithKline | Infection, Human Immunodeficiency Virus|HIV Infections | 2013-04-04 | PHASE2 |
| NCT02904369 | CONRAD|United States Agency for International Development (USAID)|Agility Clinical, Inc. | HIV | 2016-10-06 | PHASE1 |
| NCT03387462 | Public Health Foundation Enterprises, Inc.|National Institute of Mental Health (NIMH)|San Francisco Department of Public Health|Emory University|AiCure | Adherence, Medication|Risk Behavior|Pre-Exposure Prophylaxis|HIV Prevention | 2018-02-28 | PHASE4 |
| NCT02583464 | Laboratorio Elea Phoenix S.A. | Acquired Immunodeficiency Syndrome | 2014-09 | PHASE1 |
| NCT03917420 | University of North Carolina, Chapel Hill|National Institute of Allergy and Infectious Diseases (NIAID) | HIV+AIDS | 2019-03-26 | PHASE1 |
| NCT01605890 | ANRS, Emerging Infectious Diseases|Gilead Sciences|Merck Sharp & Dohme LLC | HIV-2 Infection | 2012-07 | PHASE2 |
| NCT05993767 | PENTA Foundation|Radboud University Medical Center|Baylor College of Medicine|Clinton Health Access Initiative Inc.|University of Zimbabwe|Chiang Mai University|Joint Clinical Research Center | HIV Infection | 2024-12-11 | PHASE2 |
| NCT03043326 | Asociación Civil Impacta Salud y Educación, Peru|Gilead Sciences | HIV Prevention | 2017-01-23 | |
| NCT00084136 | Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2005-05 | PHASE4 |
| NCT04050371 | University of California, San Francisco|San Francisco AIDS Foundation|California HIV+AIDS Research Program | HIV Prevention|Transgender Health | 2017-08-03 | PHASE4 |
| NCT01715636 | Andrew Carr | HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men | 2012-12 | PHASE4 |
| NCT00087464 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | NA |
| NCT07031063 | Instituto Mexicano del Seguro Social | HIV Infection|Metabolic Syndrome|Antiretroviral Treatment | 2025-04-01 | PHASE4 |
| NCT04712058 | National Taiwan University Hospital|Far Eastern Memorial Hospital|Mackay Memorial Hospital|Changhua Christian Hospital|Chung Shan Medical University|National Cheng-Kung University Hospital|Chi Mei Medical Hospital|Kaohsiung Medical University Chung-Ho Memorial Hospital|Kaohsiung Municipal Ta-Tung Hospital | HIV Infections | 2021-01-20 | NA |
| NCT00127959 | International Antiviral Therapy Evaluation Center|Gilead Sciences | HIV Infections|Hepatitis B | 2004-03 | PHASE4 |
| NCT01274780 | Juan A. Arnaiz | HIV-1 | 2011-05 | PHASE4 |
| NCT03771638 | Public Health Foundation Enterprises, Inc.|National Institute of Mental Health (NIMH)|San Francisco Department of Public Health|Emory University|AiCure | Adherence, Medication|Risk Behavior|Pre-Exposure Prophylaxis|HIV Prevention | 2019-02-01 | PHASE4 |
| NCT00102206 | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections | | PHASE2 |
| NCT00551018 | Merck Sharp & Dohme LLC | HIV Infections | 2007-12 | PHASE2 |
| NCT00642291 | Gilead Sciences | HIV Infections | 2002-11 | PHASE2 |
| NCT04593680 | Thai Red Cross AIDS Research Centre | Drug Interaction | 2022-01-24 | NA |
| NCT00641641 | Kirby Institute|Merck Sharp & Dohme LLC | HIV Infection | 2008-03 | NA |
| NCT07062614 | University Hospital, Toulouse | HIV (Human Immunodeficiency Virus) | 2025-07-03 | |
| NCT00958100 | Catholic University of the Sacred Heart | HIV+AIDS|Antiretroviral Therapy|HIV Infections | 2009-08 | PHASE2 |
| NCT02367807 | Philadelphia Fight | HIV | 2015-02 | |
| NCT00002416 | Triangle Pharmaceuticals | HIV Infections | | PHASE3 |
| NCT01709084 | Janssen-Cilag International NV | Human Immunodeficiency Virus-type 1 Infection | 2013-10-02 | PHASE3 |
| NCT02984852 | Janssen Scientific Affairs, LLC | Healthy | 2016-12 | PHASE1 |
| NCT00307489 | Gilead Sciences | Chronic Hepatitis B | 2006-03 | PHASE2 |
| NCT01583439 | Harvard School of Public Health (HSPH)|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2012-09 | NA |
| NCT04862975 | Duke University|The Emmes Company, LLC | Lactating Women on Select DOI|Breastmilk Fed Infants of Mothers on Select DOI|HIV Infections | 2024-01-09 | |
| NCT00323544 | Gilead Sciences | HIV Infections | 2004-10 | PHASE3 |
| NCT00115609 | French National Agency for Research on AIDS and Viral Hepatitis | HIV Infections|Tuberculosis | 2006-01 | PHASE3 |
| NCT04685512 | University Hospital, Caen | Covid19 | 2020-11-18 | PHASE2|PHASE3 |
| NCT00196612 | French National Agency for Research on AIDS and Viral Hepatitis|Triangle Pharmaceuticals|Gilead Sciences|Bristol-Myers Squibb|Dupont Applied Biosciences | HIV Infections | 2001-04 | PHASE3 |
| NCT06278389 | Jiangsu Aidea Pharmaceutical Group Co., Ltd.|Chengdu Aidea Pharmaceutical Technology Co., Ltd | Healthy Adult Participants | 2024-01-24 | PHASE1 |
| NCT00380159 | Alexion Pharmaceuticals, Inc.|Achillion, a wholly owned subsidiary of Alexion | Human Immunodeficiency Virus (HIV)-1 Infection | 2006-09 | PHASE2 |
| NCT00006144 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2000-10 | PHASE2 |
| NCT04853524 | Janssen Research & Development, LLC | Healthy | 2021-05-06 | PHASE1 |
| NCT03218085 | University of Minnesota|American College of Clinical Pharmacy | HIV+AIDS|Menopause|Inflammation Vagina | 2017-07-14 | |
| NCT04549467 | Fundacion IDEAA|ViiV Healthcare | Hiv|HIV-1-infection | 2020-11-17 | PHASE4 |
| NCT00221286 | University Hospital, Bonn|Hoffmann-La Roche | Chronic Hepatitis B|HIV Infections | 2004-09 | PHASE3 |